Skip to main content

Advertisement

SpringerLink
Log in

Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

P63 is a member of the p53 family, which plays a role in the differentiation of urothelium and is supposed to play a role in urothelial carcinogenesis. P53 and MIB-1 are recognised in many studies as predictive markers of progression, but few studies in the literature have examined p63. The aims of our study were to explore the expression of p63 in bladder carcinomas and to compare this expression to p53 and MIB-1, as well as to stage and grade. Tissue microarrays were performed on 158 urothelial carcinomas (56 pTa, 45 pT1 and 57≥pT2). Immunohistochemical studies were performed with p63, p53 and MIB-1 antibodies. In our study we observed that p63 immunostaining is present in all cell layers in papillary urothelial neoplasm of low malignant potential (PUNLMP), but partially lost in non-invasive papillary urothelial carcinoma low grade (NILGC) and in pT1/≥pT2 bladder cancers. P53 and MIB-1 displayed lower expression in PUNLMP/NILGC vs non-invasive papillary urothelial carcinoma high grade (NIHGC)/pT1, but there was no correlation between the expression of p63, p53 and MIB-1. Our study demonstrates that p63 expression distinguishes between PUNLMP/NILGC and NIHGC/pT1 (p=4.105). A statistical difference disserving pTa and pT1/≥pT2 with a statistical significance (p<10−6) could also be observed. P63 should be considered as an additional biomarker that might help pathologists to classify their patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Barbieri CE, Barton CE, Pietenpol JA (2003) Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway. J Biol Chem 278:51408–51414

    Article  PubMed  CAS  Google Scholar 

  2. Cho NH, Kim YB, Park TK, Kim GE, Park K, Song KJ (2003) P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma. Gynecol Oncol 91:346–353

    Article  PubMed  CAS  Google Scholar 

  3. DiComo CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Teruya-Feldstein J, Pohar K, Hoos A, Cordon-Cardo C (2002) p63 expression profiles in human normal and tumor tissue. Clin Cancer Res 8:494–501

    PubMed  CAS  Google Scholar 

  4. Geddert H, Kiel S, Heep HJ, Gabbert HE, Sarbia M (2003) The role of p63 and deltaNp63 (p40) protein expression and gene amplification in esophageal carcinogenesis. Hum Pathol 34:850–856

    Article  PubMed  CAS  Google Scholar 

  5. Habuchi T, Kinoshita H, Yamada H, Knowles M (1995) Oncogene amplification in urothéliale cancers with p53 gene mutation or MDM2 amplification. J Natl Cancer Inst 86:1331–1335

    Article  Google Scholar 

  6. Hagiwara K, McMenamin MG, Miura K, Harris CC (1999) Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primer. Cancer Res 59:14165–14169

    Google Scholar 

  7. Hara T, Kijima H, Yamamoto S, Kenmochi T, Kise Y, Tanaka H, Chino O, Shimada H, Takazawa K, Tanaka M, Inokuchi S, Makuuchi H (2004) Ubiquitous p63 expression in human esophageal squamous cell carcinoma. Int J Mol Med 14:169–173

    PubMed  CAS  Google Scholar 

  8. Harmes DC, Bresnick E, Lubin EA, Watson JK, Heim KE, Curtin JC, Suskind AM, Lamb J, DiRenzo J (2003) Positive and negative regulation of deltaN-p63 promoter activity by p53 and deltaN-p63-alpha contributes to differential regulation of p53 target genes. Oncogene 22:7607–7616

    Article  PubMed  CAS  Google Scholar 

  9. Harms K, Nozell S, Chen X (2004) The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci 61:822–842

    Article  PubMed  CAS  Google Scholar 

  10. Helpap B, Köllermann J (1999) Proliferative pattern of exophytic and superficially invasive and non-invasive low grade urothelial carcinomas. Hum Pathol 30:145–150

    Article  PubMed  CAS  Google Scholar 

  11. Helpap B, Köllermann J (2000) Assessment of basal cell status and proliferative patterns in flat and papillary urothelial lesions: a contribution to the new WHO classification of urothelial tumors of the urinary bladder. Hum Pathol 31:745–750

    Article  PubMed  CAS  Google Scholar 

  12. Helpap B, Schmitz-Dräger B, Hamilton PW, Muzzonigro G, Galosi AB, Kurth KH, Lubaroff D, Waters D, Droller MJ (2003) Molecular pathology of non-invasive urothéliale carcinomas (part I). Virchows Arch 442:309–316

    PubMed  CAS  Google Scholar 

  13. Holmang S, Johansson SL (2002) Stage Ta-T1 bladder cancer: the relationship between findings at first follow-up cystoscopy and subsequent recurrence and progression. J Urol 167:1634–1637

    Article  PubMed  Google Scholar 

  14. Jourdan F, Sebbagh N, Compérat E, Mourra N, Flahault A, Olschwang S, Hamelin R, Fléjou JF (2003) Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1 and hMSH2 immunohistochemical expression. Virchows Arch 443:115–121

    Article  PubMed  CAS  Google Scholar 

  15. Kaufmann O, Fietze E, Mengs J, Dietel M (2001) Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 116:823–830

    Article  PubMed  CAS  Google Scholar 

  16. Knowles M (2001) What we could do now: molecular pathology of bladder cancer. J Clin Pathol 54:215–221

    Article  CAS  Google Scholar 

  17. Koga F, Kawakami S, Fujii Y, Saito K, Ohtsuka Y, Iwai et al (2003) Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothéliale carcinoma of the bladder. Clin Cancer Res 9:5501–5507

    PubMed  CAS  Google Scholar 

  18. Koga F, Kawakami S, Kumagai J, Takizawa T, Ando N, Arai G, Kageyama Y, Kihara K (2003) Impaired Delta Np63 expression associates with reduced beta-catenin and aggressive phenotypes of urothelial neoplasms. Br J Cancer 88:740–747

    Article  PubMed  CAS  Google Scholar 

  19. Langner C, Ratschek M, Tsybrovskyy O, Schips L, Zigeuner R (2003) P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors. J Histochem Cytochem 51:1097–1099

    PubMed  CAS  Google Scholar 

  20. Lebret T, Bohin D, Kassardjan Z, Herve JM, Molinie V, Barre P, Lugagne PM, Botto H (2000) Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette–Guerin instillations. J Urol 163:63–67

    Article  PubMed  CAS  Google Scholar 

  21. Little NA, Jochemsen AG (2002) p63. Int J Biochem Cell Biol 34:6–9

    Article  PubMed  CAS  Google Scholar 

  22. Lu ML, Wikman F, Orntoft T, Charytonowicz E, Rabbani F, Zhang Z, Dalbagni G, Pohar KS, Yu G, Cordon-Cardo C (2002) Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome assessed by conventional and array-based methods. Clin Cancer Res 8:171–179

    PubMed  CAS  Google Scholar 

  23. Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME, Westfall MD, Roberts JR, Pietenpol JA, Carbone DP, Gonzalez AL (2003) Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 63(21):7113–7121

    PubMed  CAS  Google Scholar 

  24. Melino G, Lu X, Gasco M, Crook T, Knight RA (2003) Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci 28:663–670

    Article  PubMed  CAS  Google Scholar 

  25. Moll U (2003) The role of p63 and p73 in tumor formation and progression: coming of age towards clinical usefulness. Clin Cancer Res 9:5437–5441

    PubMed  CAS  Google Scholar 

  26. Nakanishi K, Kawai T, Torikata C (1996) Immunohistochemical evaluation of p53 oncoprotein in transitional cell carcinoma of the upper urinary tract. Hum Pathol 27:1336–1340

    Article  PubMed  CAS  Google Scholar 

  27. Nocito A, Bubendorf L, Tinner EM, Süss K, Wagner U, Forster T, et al (2001) Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 194:349–357

    Article  PubMed  CAS  Google Scholar 

  28. Park BJ, Lee SJ, Lee KSJ, Lee CH, Chang SG, Park JH et al (2000) Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res 60:3370–3374

    PubMed  CAS  Google Scholar 

  29. Pelosi G, Pasini F, Olsen Stenholm C, Pastorino U, Maisonneuve P, Sonzogni A, Maffini F, Pruneri G, Fraggetta F, Cavallon A, Roz E, Iannucci A, Bresaola E, Viale G (2002) p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J Pathol 198:100–109

    Article  PubMed  CAS  Google Scholar 

  30. Reis-Filho JS, Simpson PT, Martins A, Preto A, Gärtner F, Schmitt FC (2003) Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows arch 443:122–132

    Article  PubMed  CAS  Google Scholar 

  31. Ribeiro-Silva A, Zambelli Ramalho LN, Britto Garcia S, Zucoloto S (2003) The relationship between p63 and p53 expression in normal and neoplastic breast tissue. Arch Pathol Lab Med 127:336–340

    PubMed  CAS  Google Scholar 

  32. Richter J, Jiang F, Gorog JP (1997) Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 57:2860–2864

    PubMed  CAS  Google Scholar 

  33. Sandberg AA (2002) Cytogenetics and molecular genetics of bladder cancer: a personal view. Am Med Genet 115:173–182

    Article  Google Scholar 

  34. San Miguel Fraile P, Anton Badiola I, Ortiz Rey JA, Alvarez Alvarez C, Fernandez Costas A, Lago Fernandez M, Pelaez Boismorand E, Zungri Telo E, De La Fuente Buceta A (2003) Comparative study of the expression of p53, Ki-67, bcl-2 and CK20 in superficial transitional carcinoma of the bladder: correlation with recurrence, histological grade, and clinical stage. Actas Urol Esp 27:587–593

    PubMed  Google Scholar 

  35. Santos L, Amaro T, Costa C, Pereira S, Bento MJ, Lopes P et al (2003) Ki-67 index enhances the prognostic accuracy of the urothéliale superficial bladder carcinoma risk group classification. Int J Cancer 105:267–272

    Article  PubMed  CAS  Google Scholar 

  36. Senoo M, Matsumura Y, Habu S (2002) TAp63gamma (p51A) and dNp63alpha (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression. Oncogene 21:2455–2465

    Article  PubMed  CAS  Google Scholar 

  37. Shariat SF, Kim J, Raptidis G, Ayala G, Lerner S (2003) Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 61:1140–1145

    Article  PubMed  Google Scholar 

  38. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A Montironi R, McKeon F, Loda M (2000) p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157:1769–1775

    PubMed  CAS  Google Scholar 

  39. Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM (2003) The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol 169:1219–1228

    Article  PubMed  CAS  Google Scholar 

  40. Soloway MS, Sofer M, Vaidya A (2002) Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 167:1573–1583

    Article  PubMed  Google Scholar 

  41. Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A, Del Sal G, Levrero M, Sacchi A, Oren M, Blandino G (2002) Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 277:18817–18826

    Article  PubMed  CAS  Google Scholar 

  42. Thurfjell N, Coates PJ, Uusitalo T, Mahani D, Dabelsteen E, Dahlqvist A, Sjostrom B, Roos G, Nylander K (2004) Complex p63 mRNA isoform expression patterns in squamous cell carcinoma of the head and neck. Int J Oncol 25(1):27–35

    PubMed  CAS  Google Scholar 

  43. Tiguert R, Lessard A, So A, Fradet Y (2002) Prognostic markers in muscle invasive bladder cancer. World J Urol 20:190–195

    PubMed  CAS  Google Scholar 

  44. Urist M J, Di Como CJ, Lu ML, Charytonowicz E, Verbel D, Crum CP et al (2002) Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 161:1199–1206

    PubMed  CAS  Google Scholar 

  45. World Health Organization Classification of Tumors (2004) Tumors of the urinary system and male genital organs. In: Eble J et al (eds) IARC, Lyon

  46. Wu G, Nomoto S, Hoque MO, Dracheva T, Osada M, Lee CC, Dong SM, Guo Z, Benoit N, Cohen Y, Rechthand P, Califano J, Moon CS, Ratovitski E, Jen J, Sidransky D, Trink B (2003) DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res 63:2351–2357

    PubMed  CAS  Google Scholar 

  47. Yan Y, Andriole GL, Humphrey PA, Kibel AS (2002) Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinomas of bladder and effects of clinicopathologic and biochemical factors. Cancer 95:1239–1246

    Article  PubMed  Google Scholar 

  48. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C, McKeon F (1999) p63 is essential for regenerative proliferation in limb, craniofacial, and in epithelial development. Nature 398:714–718

    Article  PubMed  CAS  Google Scholar 

  49. Zigeuner R, Tsybrovskyy O, Ratschek M, Rehak P, Lipsky K, Langner C (2004) Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinomas. Urology 63:1079–1083

    Article  PubMed  Google Scholar 

Download references

Acknowledgement

Brigitte Radenen is acknowledged for excellent technical assistance.

Author information

Authors and Affiliations

  1. Service Central d'Anatomie et Cytologie Pathologiques et d'Urologie, Hôpital La Pitié-Salpêtrière, 83, Bd de l'Hôpital, 75013, Paris, France

    Eva Compérat, Emmanuel Chartier-Kastler, Stephane Bart, Annick Delcourt, Richard François & Fréderique Capron

  2. Service Central d'Anatomie et Cytologie Pathologiques et d'Urologie, Departement d'Epidemiologie et de Santé Publique Nord, Hôpital d'Instructions des Armée Val-de Grace, 74 boulevard Port Royal, 75230, Paris, France

    Philippe Camparo, Rachel Haus & Alain Houlgatte

  3. Service Central d'Anatomie et Cytologie Pathologiques, Groupe hospitalier Cochin, Saint Vincent de Paul, 27, rue du Faubourg Saint Jaques, 75679, Paris, Cedex 14, France

    Annick Vieillefond

Authors
  1. Eva Compérat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philippe Camparo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rachel Haus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emmanuel Chartier-Kastler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stephane Bart
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Annick Delcourt
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alain Houlgatte
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Richard François
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Fréderique Capron
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Annick Vieillefond
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eva Compérat.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Compérat, E., Camparo, P., Haus, R. et al. Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases. Virchows Arch 448, 319–324 (2006). https://doi.org/10.1007/s00428-005-0092-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-005-0092-2

Keywords

Search

Navigation